| Identification | Back Directory | [Name]
GSK-239512 | [CAS]
720691-69-0 | [Synonyms]
GSK-239512
GSK-239512 720691-69-0
2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-
1-(6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)pyridin-3-yl)pyrrolidin-2-one | [Molecular Formula]
C23H27N3O2 | [MDL Number]
MFCD27922168 | [MOL File]
720691-69-0.mol | [Molecular Weight]
377.48 |
| Chemical Properties | Back Directory | [Boiling point ]
607.6±55.0 °C(Predicted) | [density ]
1.239±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Solid | [pka]
9.02±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
GSK239512 is a potent and brain penetrated H3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD)[1]. | [IC 50]
H3 receptor | [References]
[1] Grove RA, et, al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr Alzheimer Res. 2014 Jan;11(1):47-58. DOI:10.2174/1567205010666131212110148 |
|
|